世界の非アルコール性脂肪性肝炎（NASH）治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4157 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、非アルコール性脂肪性肝炎（NASH）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ビタミンE＆ピオグリタゾン、オベチコール酸（OCA）、エラフィブラノール、セロンセルチブ＆セニクリビロク）、用途別市場規模（病院薬局、オンラインプロバイダー、ドラッグストア）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・非アルコール性脂肪性肝炎（NASH）治療薬の市場動向 ・企業の競争状況、市場シェア ・非アルコール性脂肪性肝炎（NASH）治療薬の種類別市場規模（ビタミンE＆ピオグリタゾン、オベチコール酸（OCA）、エラフィブラノール、セロンセルチブ＆セニクリビロク） ・非アルコール性脂肪性肝炎（NASH）治療薬の用途別市場規模（病院薬局、オンラインプロバイダー、ドラッグストア） ・非アルコール性脂肪性肝炎（NASH）治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・非アルコール性脂肪性肝炎（NASH）治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・非アルコール性脂肪性肝炎（NASH）治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・非アルコール性脂肪性肝炎（NASH）治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・非アルコール性脂肪性肝炎（NASH）治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AstraZeneca、Conatus Pharmaceuticals、Enzo Biochem、Galmed Pharmaceuticals、Genfit、Gilead、Horizon Pharma、Immuron、Intercept Pharmaceuticals、Novo Nordisk） ・結論

Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
This market is boosted by the growing prevalence of diabetes and obesity, and high investments for research and development, which leads to rising demand for NASH and others nonalcoholic fatty liver diseases (NAFLD) therapies in the market. As per the regional analysis, the well-established healthcare infrastructure with the high adoption rate of new technologies and increasing research activities, makes North America dominate this market.

Market Analysis and Insights: Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market
The global Non-Alcoholic Steatohepatitis (NASH) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Non-Alcoholic Steatohepatitis (NASH) Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Non-Alcoholic Steatohepatitis (NASH) Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market.

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Scope and Market Size
Non-Alcoholic Steatohepatitis (NASH) Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Non-Alcoholic Steatohepatitis (NASH) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc

Segment by Application
Hospital Pharmacy
Online Provider
Retail Pharmacy

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Vitamin E & Pioglitazone
1.2.3 Obeticholic Acid (OCA)
1.2.4 Elafibranor
1.2.5 Selonsertib & Cenicriviroc
1.3 Market by Application
1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Perspective (2016-2027)
2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Growth Trends by Regions
2.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Dynamic
2.3.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trends
2.3.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
2.3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
2.3.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue
3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue (2016-2021)
3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue
3.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio
3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2020
3.5 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players Head office and Area Served
3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Type
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2016-2021)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2022-2027)

5 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Application
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Application (2016-2021)
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2016-2027)
6.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
6.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021)
6.2.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027)
6.2.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2027)
6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
6.3.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021)
6.3.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027)
6.3.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2027)
6.4 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
6.4.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021)
6.4.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2016-2027)
7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
7.2.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021)
7.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027)
7.2.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2027)
7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
7.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021)
7.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027)
7.3.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2027)
7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
7.4.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021)
7.4.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2016-2027)
8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
8.2.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
8.3.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region
8.4.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2016-2027)
9.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
9.2.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2027)
9.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
9.3.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2027)
9.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
9.4.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2016-2027)
10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
10.2.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
10.3.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
10.4.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.1.5 AstraZeneca Recent Development
11.2 Conatus Pharmaceuticals
11.2.1 Conatus Pharmaceuticals Company Details
11.2.2 Conatus Pharmaceuticals Business Overview
11.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.2.5 Conatus Pharmaceuticals Recent Development
11.3 Enzo Biochem
11.3.1 Enzo Biochem Company Details
11.3.2 Enzo Biochem Business Overview
11.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.3.5 Enzo Biochem Recent Development
11.4 Galmed Pharmaceuticals
11.4.1 Galmed Pharmaceuticals Company Details
11.4.2 Galmed Pharmaceuticals Business Overview
11.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.4.5 Galmed Pharmaceuticals Recent Development
11.5 Genfit
11.5.1 Genfit Company Details
11.5.2 Genfit Business Overview
11.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.5.5 Genfit Recent Development
11.6 Gilead
11.6.1 Gilead Company Details
11.6.2 Gilead Business Overview
11.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.6.5 Gilead Recent Development
11.7 Horizon Pharma
11.7.1 Horizon Pharma Company Details
11.7.2 Horizon Pharma Business Overview
11.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.7.5 Horizon Pharma Recent Development
11.8 Immuron
11.8.1 Immuron Company Details
11.8.2 Immuron Business Overview
11.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.8.5 Immuron Recent Development
11.9 Intercept Pharmaceuticals
11.9.1 Intercept Pharmaceuticals Company Details
11.9.2 Intercept Pharmaceuticals Business Overview
11.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.9.5 Intercept Pharmaceuticals Recent Development
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Details
11.10.2 Novo Nordisk Business Overview
11.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.10.5 Novo Nordisk Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Vitamin E & Pioglitazone
Table 3. Key Players of Obeticholic Acid (OCA)
Table 4. Key Players of Elafibranor
Table 5. Key Players of Selonsertib & Cenicriviroc
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2016-2021)
Table 10. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2022-2027)
Table 12. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trends
Table 13. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
Table 14. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
Table 15. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
Table 16. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players (2016-2021)
Table 18. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2020)
Table 19. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
Table 23. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2016-2021)
Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2016-2021)
Table 31. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 63. AstraZeneca Company Details
Table 64. AstraZeneca Business Overview
Table 65. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 66. AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 67. AstraZeneca Recent Development
Table 68. Conatus Pharmaceuticals Company Details
Table 69. Conatus Pharmaceuticals Business Overview
Table 70. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 71. Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 72. Conatus Pharmaceuticals Recent Development
Table 73. Enzo Biochem Company Details
Table 74. Enzo Biochem Business Overview
Table 75. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 76. Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 77. Enzo Biochem Recent Development
Table 78. Galmed Pharmaceuticals Company Details
Table 79. Galmed Pharmaceuticals Business Overview
Table 80. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 81. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 82. Galmed Pharmaceuticals Recent Development
Table 83. Genfit Company Details
Table 84. Genfit Business Overview
Table 85. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 86. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 87. Genfit Recent Development
Table 88. Gilead Company Details
Table 89. Gilead Business Overview
Table 90. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 91. Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 92. Gilead Recent Development
Table 93. Horizon Pharma Company Details
Table 94. Horizon Pharma Business Overview
Table 95. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 96. Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 97. Horizon Pharma Recent Development
Table 98. Immuron Company Details
Table 99. Immuron Business Overview
Table 100. Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 101. Immuron Recent Development
Table 102. Intercept Pharmaceuticals Company Details
Table 103. Intercept Pharmaceuticals Business Overview
Table 104. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 105. Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 106. Intercept Pharmaceuticals Recent Development
Table 107. Novo Nordisk Company Details
Table 108. Novo Nordisk Business Overview
Table 109. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 110. Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 111. Novo Nordisk Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type: 2020 VS 2027
Figure 2. Vitamin E & Pioglitazone Features
Figure 3. Obeticholic Acid (OCA) Features
Figure 4. Elafibranor Features
Figure 5. Selonsertib & Cenicriviroc Features
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2020 VS 2027
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Online Provider Case Studies
Figure 9. Retail Pharmacy Case Studies
Figure 10. Non-Alcoholic Steatohepatitis (NASH) Drugs Report Years Considered
Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions: 2020 VS 2027
Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2022-2027)
Figure 15. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players in 2020
Figure 16. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2020
Figure 18. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2016-2021)
Figure 19. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2022-2027)
Figure 20. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2016-2027)
Figure 22. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2016-2027)
Figure 23. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2016-2027)
Figure 24. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2016-2027)
Figure 28. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2016-2027)
Figure 29. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2016-2027)
Figure 30. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2016-2027)
Figure 40. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2016-2027)
Figure 48. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2016-2027)
Figure 49. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2016-2027)
Figure 50. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2016-2027)
Figure 56. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. AstraZeneca Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 60. Conatus Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 61. Enzo Biochem Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 62. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 63. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 64. Gilead Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 65. Horizon Pharma Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 66. Immuron Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 67. Intercept Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 68. Novo Nordisk Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

---